Quratis Securing Vaccine Sovereignty 'Start-up'


Korea's first anti-tuberculosis vaccine for adults, clinical approval of phase 2a.

Expect to establish GMP plant this year, and expect to be a cornerstone of its global expansion.



Quratis announced on Monday that it has recently received approval from the Ministry of Food and Drug Safety for a two-a-phase clinical trial on the nation's first anti-tuberculosis vaccine for adults.



The approved clinical tests will be conducted at Yonsei Medical Center Severance Hospital and will evaluate the safety of tuberculosis vaccines for healthy adults for about a year and a half and explore immunological origin and efficacy, according to the company.



We will make efforts to successfully carry out the clinical trials for this 2a prize, said Kang Young-ae, a professor of respiratory medicine at Yonsei Medical Center Severance Hospital, which is in charge of clinical trials, who recently diagnosed that the number of exposure to tuberculosis in hospitals and collective facilities in Korea is increasing.